Lipocine vs 60 Degrees Pharmaceuticals
Lipocine is the larger business, with $2.0m of revenue in fiscal 2025 against $1.0m for 60 Degrees Pharmaceuticals (2.0 times as much). 60 Degrees Pharmaceuticals grew faster (65.5% against -82.3%). Lipocine kept more of each dollar of sales as profit: a net margin of -487.1% against -732.5%.
| Latest fiscal year | LipocineLPCN, 2025 | 60 Degrees PharmaceuticalsSXTP, 2025 |
|---|---|---|
| Revenue | $2.0m | $1.0m |
| Revenue growth | -82.3% | 65.5% |
| Net income | −$9.6m | −$7.4m |
| Operating margin | -524.7% | — |
| Net margin | -487.1% | -732.5% |
| Return on equity | -54.3% | -196.4% |
| Free cash flow | −$9.8m | −$7.0m |
| Cash | $5.2m | $1.5m |
| Total debt | $0 | $152,775 |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 14 | — |
| Market value | $12.0m | $2.6m |
| Price vs our value range | — | — |
| Moat score | 12 (Weak) | — |
| Insider trades, 12 months | 7 buys, 0 sales | 4 buys, 0 sales |